Chenghe Acquisition (CHEA) +153%. 4D Molecular Therapeutics (FDMT) +54%. BioRestorative Therapies (BRTX) +26% Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc ...
Source LinkChenghe Acquisition (CHEA) +153%. 4D Molecular Therapeutics (FDMT) +54%. BioRestorative Therapies (BRTX) +26% Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc ...
Source Link
Comments